A new preclinical study from a joint Swiss research team indicates that giving immunotherapy before surgery to remove glioblastoma tumors may lead to considerably better treatment outcomes than the current standard of surgery followed by immunotherapy. The findings, which have implications for how brain cancer treatments are sequenced, were reported in a recent press release and could influence future clinical trial designs and therapeutic strategies.
The study, conducted in animal models, compared two treatment schedules: one where immunotherapy was administered prior to surgical resection of the tumors, and another where tumors were removed first and then immunotherapy was given. Results showed that the group receiving immunotherapy before surgery experienced improved outcomes, suggesting that the timing of immunotherapy relative to surgery is critical in glioblastoma management. This is particularly significant because glioblastoma is an aggressive and difficult-to-treat brain cancer with a poor prognosis, and any improvement in treatment efficacy could have a meaningful impact on patient survival.
While these findings are preclinical and require validation in human trials, they offer a promising avenue for optimizing treatment protocols. The study aligns with a growing body of research exploring neoadjuvant immunotherapy—treatment given before the primary intervention—in various cancers. By priming the immune system to recognize and attack tumor cells before surgery, it may be possible to reduce the risk of recurrence and improve overall response to therapy.
The implications extend beyond academia and clinical practice. Companies developing immunotherapies for brain cancer, such as Calidi Biotherapeutics Inc. (NYSE American: CLDI), are likely to take note of these findings as they consider the optimal positioning of their products in treatment regimens. Calidi Biotherapeutics is among the enterprises focused on novel cancer treatments, and this research could inform their development strategies and potential partnerships with surgical teams.
The Swiss team’s work underscores the importance of treatment sequencing, a factor that is sometimes overlooked in oncology. As more data emerges, clinicians may need to rethink the traditional paradigm of ‘surgery first, then adjuvant therapy.’ Instead, a neoadjuvant approach could become a standard part of glioblastoma care, potentially improving outcomes for a patient population that has seen little progress in recent decades.
Further research is needed to determine the optimal timing, dosing, and patient selection for neoadjuvant immunotherapy in glioblastoma. Additionally, the findings must be replicated in larger, more diverse animal models and eventually in human clinical trials. Nevertheless, this study provides a strong rationale for investigating this approach more deeply.
For now, the scientific community watches with interest as this line of inquiry develops. The potential to shift the treatment paradigm for glioblastoma is a compelling reason to follow these results closely. Should future studies confirm these findings, they could lead to changes in standard-of-care protocols and offer new hope to patients facing this devastating disease.
